CClinicalTrials.gg
Active, not recruitingNCT04734847IcBrainStimUpdated Jun 17, 2026

Motor Cortical Neuromodulation in Women With Interstitial Cystitis/Bladder Pain Syndrome

An interventional study of Repetitive Transcranial Magnetic Stimulation (rTMS) and Sham Repetitive Transcranial Magnetic Stimulation (Sham-rTMS) in Interstitial Cystitis and Bladder Pain Syndrome, sponsored by University of Southern California. Active, not recruiting at 1 site in United States. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-17.

Sponsored by University of Southern California · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
50
Allocation
Randomized
Ages
18 Years and older
Sex
Female
01

Study summary

Interstitial Cystitis/Bladder Pain Syndrome (IC/BPS) is a common, chronic, and debilitating condition in women. Preliminary evidence suggests that IC/BPS pain can be reduced applying non-invasive repetitive transcranial magnetic stimulation (rTMS) to areas of the brain that regulate pelvic floor muscle activity. However, prior studies have examined rTMS in a very limited sample and have not examined changes in brain or pelvic floor muscle activity to determine the mechanism of rTMS for IC/BPS. This study is designed to directly address these limitations.

Read the detailed description

Interstitial Cystitis/Bladder Pain Syndrome (IC/BPS) is a common, chronic, and debilitating condition in women. The underlying cause of IC/BPS remains unknown. We recently published the first functional magnetic resonance imaging (fMRI) study comparing brain function in women with IC/BPS to healthy women. We found that women with IC/BPS have altered resting activity in supplementary motor area (SMA). Specifically, these changes appear in a part of SMA that we have shown to control pelvic floor muscle activity. We call this part of SMA "pelvic-SMA". Our results provide the first potential explanation for extensive published reports of increased pelvic floor muscle activity in women with IC/BPS. We hypothesize that we are observing evidence of an important theory of chronic pain: motor cortical changes occur that are initially beneficial to increase protective muscle activity but are ultimately maladaptive and perpetuate pain. If this theory is true, it should be possible to reduce pain and muscle activity by improving brain activity. The proposed work is to do exactly that. Using non-invasive repetitive transcranial magnetic stimulation (rTMS) directed at pelvic-SMA, we aim to determine if we can reduce pain (Aim 1), improve resting brain activity (fMRI) and resting pelvic floor muscle electromyographic (EMG) activity in IC/BPS (Aim 2), and to link the pain reductions to fMRI/EMG improvements to develop a causal mediation model of IC/BPS symptoms (Aim 3). We will recruit 50 women with IC/BPS to participate in the study, and participants will be randomized to 2 groups of 25: high-frequency (active) or sham (inert). Our preliminary data suggest that high-frequency stimulation is the best stimulation protocol for reducing pain and improving pelvic-SMA activity and resting pelvic floor muscle activity. Our preliminary results agree with a large body of literature suggesting that high-frequency rTMS applied to motor cortex is the best stimulus paradigm to reduce pain, but our proposed work has the potential to greatly innovate the field of non-invasive brain stimulation for pain by providing a mechanism by which the stimulation can improve deficiencies in motor function in chronic pain patients.

02

Conditions studied

  • Interstitial Cystitis
  • Bladder Pain Syndrome

Keywords

  • Chronic Pain
  • Transcranial Magnetic Stimulation
03

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Inclusion criteria

  1. Be at least 18 years old.
  2. Be female.
  3. Have a diagnosis of IC/BPS by the referring physician, with urologic symptoms present a majority of the time during the most recent 3 months
  4. Screen within standard limits for pelvic pain

Exclusion criteria

Exclusion Criteria:

  1. Symptomatic urethral stricture
  2. On-going neurological conditions affecting the bladder or bowel
  3. Active auto-immune or infectious disorders
  4. History of cystitis caused by tuberculosis or radiation or chemotherapies
  5. History of non-dermatologic cancer
  6. Current major psychiatric disorders
  7. Severe cardiac, pulmonary, renal, or hepatic disease
  8. Conditions or the use of medical devices that are contraindications for either fMRI or rTMS procedures, including pregnancy, seizure disorders, or chronic headaches
04

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
50 participants (estimated)

Study arms

  • Active comparator
    High-frequency rTMS

    Intensity: rTMS treatment intensity determined using resting motor threshold (RMT). Treatment will be delivered at 80% of the RMT. Site of Stimulation: Region of supplementary motor area (SMA) that regulates pelvic floor muscle activity. This target is defined in Montreal Neurological Institute (MNI) Coordinates of X=-2, Y=-16, and Z=68 mm. Frequency: 10 Hz. Duration: 20 Trains, 10 second duration, 50 second inter-train interval. Total number of pulses per session: 2000. Total number of session: 5 (one session per day for 5 consecutive days).

    Device: Repetitive Transcranial Magnetic Stimulation (rTMS)

  • Sham comparator
    Sham rTMS

    Identical to the High-frequency rTMS arm except delivered with an inert "sham" stimulation coil.

    Device: Sham Repetitive Transcranial Magnetic Stimulation (Sham-rTMS)

Interventions

  • DeviceRepetitive Transcranial Magnetic Stimulation (rTMS)

    Non-invasive magnetic stimulation of the brain

  • DeviceSham Repetitive Transcranial Magnetic Stimulation (Sham-rTMS)

    Device that appears identical to the active rTMS device, but does not produce any magnetic field and does not stimulate the brain.

05

What researchers measure

Primary outcomes

  1. Longer-term Pain

    Change in Visual Analog Scale of Pain. This scale ranges from 0 (no pain) to 10 (worst pain imaginable), so higher scores indicate more pain.

    Time frame: Before first treatment to 3 weeks after last treatment

  2. Shorter-term Pain

    Change in Visual Analog Scale of Pain. This scale ranges from 0 (no pain) to 10 (worst pain imaginable), so higher scores indicate more pain.

    Time frame: Before first treatment to 1 day later just before second treatment

  3. Global Response Assessment

    Global Response Assessment (GRA)

    Time frame: 3 weeks after last treatment

Secondary outcomes

  1. fALFF in Pelvic-SMA

    Change in fractional amplitude of low-frequency fluctuations (fALFF) derived from functional magnetic resonance imaging (fMRI) in targeted region of the brain (pelvic-SMA)

    Time frame: One hour before and one hour after first treatment

  2. Pelvic floor muscle activity

    Change in activity of pelvic floor muscles as measured by electromyography (EMG). EMG is a physiological parameter measuring the electrical potential generated by a muscle, indicative of its activity. EMG is measured in micro-volts and then converted to percent change.

    Time frame: Just before to between five and ten minutes after start of first treatment

06

Study locations

1 site
  • University of Southern California
    Los Angeles, California 90049, United States
07

References and documents

Publications

  • Johnson EV, Bachmann M, Yani MS, Eckel SP, Garcia GI, Rodriguez LV, Kutch JJ. Reducing pain by improving brain and muscle activity with motor cortical neuromodulation in women with interstitial cystitis/bladder pain syndrome: a study protocol for a randomized controlled trial. Trials. 2024 Sep 12;25(1):609. doi: 10.1186/s13063-024-08450-w. PubMed 39261949 ↗

Individual participant data

Plan to share: No

08

Registry details

Key details

Study ID
NCT04734847
Lead sponsor
University of Southern California
Responsible party
Jason Kutch (Associate Professor, University of Southern California) — Principal investigator
First posted
Feb 2, 2021
Start date
Jun 1, 2021
Primary completion
May 20, 2026
Completion
Oct 30, 2026 (estimated)
Last update
Jun 17, 2026

Study contacts

Jason J Kutch, PhD
principal investigator · University of Southern California

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion